New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
07:24 EDTADXS, VRTX, PLX, ISIS, CYTK, RNA, NPSP, GEVA, CNAT, XOMA, RARE, NLNK, FOLDCanaccord to hold a conference
Orphan Drugs 1:1 Day will be held in New York on February 24.
News For ADXS;CNAT;CYTK;FOLD;GEVA;ISIS;NLNK;NPSP;PLX;RARE;RNA;VRTX;XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 27, 2015
16:06 EDTCNATConatus initiated with a Buy at Brean Capital
Subscribe for More Information
April 24, 2015
10:22 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
09:32 EDTISISJPMorgan Smid biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 23, 2015
10:30 EDTNLNKOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK PNK INFN WUBA MLNX CREE SKX CMG NOW FTNT
09:04 EDTRAREUltragenyx granted additional ODD for triheptanoin
Subscribe for More Information
07:19 EDTCNATConatus results at EASL meeting support emricasan registration pathway in NASH
Conatus Pharmaceuticals announced that posters providing detailed results from four recently completed clinical trials of emricasan, the company's first-in-class, orally active pan-caspase protease inhibitor, are being presented this week at The International Liver Congress 2015. Results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with acute-on-chronic liver failure, or ACLF, and Phase 2 double-blind, placebo-controlled clinical trial of emricasan in patients with nonalcoholic fatty liver disease, or NAFLD, including the subset of NAFLD patients with nonalcoholic steatohepatitis, or NASH, are addressed in two late-breaker posters. Conatus intends to include NASH-driven cirrhosis in its initial registration strategy for emricasan.
05:40 EDTPLXProtalix assumed with a Buy from Hold at Jefferies
Jefferies upgraded Protalix to Buy after assuming coverage of the name and raised its price target for shares to $2.60 from $2.00. The firm says Protalix's pipeline is growing beyond Elelyso.
April 22, 2015
16:25 EDTISISIsis Pharmaceuticals reports positive data from ISIS-TTR Rx
Subscribe for More Information
11:52 EDTADXSAdvaxis management to meet with Jefferies
Meeting to be held in New York on April 28 hosted by Jefferies.
10:53 EDTNLNKOptions with decreasing implied volatility
Subscribe for More Information
07:41 EDTRAREUltragenyx announces positive data from triheptanoin trial
Subscribe for More Information
07:07 EDTGEVAEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 21, 2015
13:34 EDTVRTXGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
13:01 EDTADXSAdvaxis presents Lm-LLO cancer immunotherapy data at AACR meeting
Advaxis announced the data of one clinical and two preclinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the American Association for Cancer Research Annual Meeting 2015, held April 18 22 in Philadelphia, Pennsylvania. On Tuesday, April 21, Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center, presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies. The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal. Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs reported at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.
12:33 EDTVRTXOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTVRTXVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
08:14 EDTVRTXGilead should buy Vertex, says Bernstein
Subscribe for More Information
April 20, 2015
16:40 EDTPLXCamber Capital reports 5.37% passive stake in Protalix
07:20 EDTADXS, ISISAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTRAREAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use